Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
cancer
8
×
life sciences
national blog main
8
×
national top stories
8
×
san francisco blog main
san francisco top stories
boston top stories
clinical trials
ipo
national
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
new york top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
venture capital
wisconsin blog main
wisconsin top stories
cancer immunotherapy
deals
novartis
sanofi
startups
abbvie
biogen
boehringer ingelheim
What
ipo
8
×
medicines
bio
cancer
life
public
roundup
science
companies
company
covid
developing
files
firms
new
plans
proteins
research
revolution
sciences
week
acquisitions
activity
advance
announced
approvals
arena’s
biogen
biology
biotechs
blood
bounty
broader
cancer’s
ceo
cig
clamped
club
collabs
comeback
Language
unset
Current search:
cancer
×
" national top stories "
×
" national blog main "
×
ipo
×
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M